- Home
- KTB vs PTGX Comparison
KTB vs PTGX Comparison
Compare KTB & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KTB
- PTGX
- Stock Information
- Founded
- KTB 2018
- PTGX 2006
- Country
- KTB United States
- PTGX United States
- Employees
- KTB N/A
- PTGX N/A
- Industry
- KTB Apparel
- PTGX Biotechnology: Pharmaceutical Preparations
- Sector
- KTB Consumer Discretionary
- PTGX Health Care
- Exchange
- KTB Nasdaq
- PTGX Nasdaq
- Market Cap
- KTB 3.6B
- PTGX 2.9B
- IPO Year
- KTB N/A
- PTGX 2016
- Fundamental
- Price
- KTB $63.51
- PTGX $53.34
- Analyst Decision
- KTB Strong Buy
- PTGX Strong Buy
- Analyst Count
- KTB 6
- PTGX 9
- Target Price
- KTB $87.50
- PTGX $67.11
- AVG Volume (30 Days)
- KTB 601.1K
- PTGX 998.2K
- Earning Date
- KTB 07-31-2025
- PTGX 08-05-2025
- Dividend Yield
- KTB 3.27%
- PTGX N/A
- EPS Growth
- KTB 3.07
- PTGX N/A
- EPS
- KTB 4.07
- PTGX 0.86
- Revenue
- KTB $2,599,277,000.00
- PTGX $207,801,000.00
- Revenue This Year
- KTB $18.27
- PTGX N/A
- Revenue Next Year
- KTB $10.96
- PTGX $47.15
- P/E Ratio
- KTB $15.61
- PTGX $61.84
- Revenue Growth
- KTB 1.08
- PTGX N/A
- 52 Week Low
- KTB $50.00
- PTGX $30.67
- 52 Week High
- KTB $96.80
- PTGX $60.60
- Technical
- Relative Strength Index (RSI)
- KTB 39.91
- PTGX 58.33
- Support Level
- KTB $63.20
- PTGX $54.48
- Resistance Level
- KTB $70.66
- PTGX $57.18
- Average True Range (ATR)
- KTB 1.80
- PTGX 2.04
- MACD
- KTB -0.72
- PTGX -0.09
- Stochastic Oscillator
- KTB 22.23
- PTGX 57.13
About KTB Kontoor Brands Inc.
Kontoor Brands Inc is a lifestyle apparel company. It is engaged in designing, manufacturing, sourcing, marketing, and distribution of its portfolio of brands, including Wrangler and Lee. It manufactures its products in owned and leased facilities and distributes the products through both brick-and-mortar and e-commerce retailers. The Company has two reportable segments: Wrangler and Lee. It generates the majority of its revenue from the Wrangler segment. The company's geographical segments are the United States and International, of which the majority of its revenue comes from the United States.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.